TheraVet announced the signature of a non-exclusive commercial distribution agreement for its BIOCERA-VET® bone substitute in France with Centravet. The agreement covers the BIOCERA-VET®-Bone Surgery (BS) and BIOCERA-VET®-Osteosarcoma (OSA) product lines. TheraVet is continuing its product lines commercial roll-out across strategic regions.

This involves the setup of own sales forces and the signing of partnerships with top-tier distributors capable of speeding up the roll-out by providing comprehensive geographical coverage. As part of this strategy, after announcing the launch of BIOCERA-VET®-BS in October 2021 and BIOCERA-VET®-OSA in December 2021, TheraVet is strengthening its sales organization by signing a distribution agreement with Centravet.